The European Medicines Agency (EMA) has recommended marketing authorization for Zegalogue (dasiglucagon) for the treatment of severe hypoglycemia in patients aged 6 years and older with diabetes. Severe hypoglycemia is a complication that can occur in people with diabetes who take insulin or certain medications, and can lead to serious problems such as loss of consciousness and coma. Zegalogue works by increasing blood glucose levels through activation of hepatic glucagon receptors. Clinical studies have shown that Zegalogue reduces the time required to increase plasma glucose compared with placebo, with common side effects being nausea, vomiting, and headache. The recommendation by the EMA is awaiting ratification by the European Commission.
Source link
Severe Hypoglycemia in Diabetes Drug Approved in Europe
